Chester County News and Community Website
WEST CHESTER, PA — Molecular Targeting Technologies, Inc. (MTTI) has unveiled significant preclinical results for its proprietary Ac-EBTATE radiopharmaceutical, demonstrating remarkable efficacy against somatostatin receptor-2-positive neuroendocrine tumors (NETs), including small …
Promising New Radiopharmaceutical Shows Breakthrough Potential in Cancer Treatment Read More
WASHINGTON, D.C. — The Food and Drug Administration (FDA) recently granted accelerated approval to Epkinly (epcoritamab-bysp), a new treatment option for adults with relapsed or refractory follicular lymphoma (FL). This …
FDA Grants Accelerated Approval to New Treatment for Relapsed Follicular Lymphoma Read More
WASHINGTON, D.C. — The Food and Drug Administration (FDA) recently granted accelerated approval for a new treatment combination for adults with KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC). …
FDA Grants Accelerated Approval to New Colorectal Cancer Treatment Read More
WASHINGTON, D.C. — The FDA on Wednesday granted full approval to the drug selpercatinib, marketed as Retevmo, for treating advanced thyroid cancer in both adults and children aged 2 and …
FDA Grants Full Approval to Retevmo for Advanced Thyroid Cancer Read More WASHINGTON, D.C. — In a significant advancement for patients with rare blood diseases, the U.S. Food and Drug Administration (FDA) has given its nod to Bkemv (eculizumab-aeeb), the first interchangeable …
FDA Approves Bkemv, A Potentially Game-Changing Treatment for Rare Blood Diseases Read More
HORSHAM, PA — In a significant medical breakthrough, Johnson & Johnson recently announced FDA’s approval of CARVYKTI® for the treatment of adult patients with multiple myeloma. This approval marks a …
FDA Approves Johnson & Johnson’s Innovative, Immuno-Targeted Multiple Myeloma Therapy, CARVYKTI Read More
NEWTOWN SQUARE, PA — In recent developments from the pharmaceutical industry, ArriVent BioPharma Inc. (Nasdaq: AVBP), a notable player in the arena of breakthrough cancer therapy, has seen a transformative …
ArriVent BioPharma Unveils Promising Developments and Strong Financial Performance in 2023 Read More
PLYMOUTH MEETING, PA — The U.S. Food and Drug Administration (FDA) has granted Orphan Drug designation to Harmony Biosciences Holdings, Inc.’s (Nasdaq: HRMY) pitolisant for the treatment of Prader-Willi syndrome …
Harmony Biosciences Secures FDA Orphan Drug Designation for Pitolisant in Prader-Willi Syndrome Treatment Read More
PHILADELPHIA, PA — The biotech firm Cabaletta Bio, Inc. (Nasdaq: CABA) has secured an Orphan Drug Designation (ODD) from the U.S. Food and Drug Administration (FDA) for its investigational therapy, …
FDA Awards Orphan Drug Designation to Cabaletta’s Innovative Myositis Therapy Read More
WAYNE, PA — Neuraptive Therapeutics Inc. recently announced that its novel treatment for peripheral nerve injury, NTX-001, has received Orphan Drug Designation from the United States Food and Drug Administration …
Neuraptive Therapeutics Earns FDA Orphan Drug Designation for Novel Peripheral Nerve Injury Treatment Read More